Background/Objectives: Sarcopenia is a frequent complication of cirrhosis and is associated with poor clinical outcomes. Computed tomography (CT) is the reference standard for diagnosis but is limited by cost and accessibility. This study aimed to evaluate the diagnostic performance of circulating myokines and adipokines and develop a simple clinical prediction model for sarcopenia in patients with compensated cirrhosis. METHODS: One hundred sixteen patients with compensated cirrhosis (Child-Pugh scoreâ¤8) were prospectively enrolled. Sarcopenia was defined by CT-based skeletal muscle index at the L3 level (SMI-L3<42 cm(2)/m(2) in men and <38 cm(2)/m(2) in women). Serum myostatin, follistatin, and adiponectin levels were measured using enzyme-linked immunosorbent assays. Diagnostic accuracy was compared using the area under the receiver operating characteristic (AUROC) curve and predictors of sarcopenia were identified using logistic regression modeling. RESULTS: Sarcopenia was present in 32.8%. Sarcopenic individuals were older, had lower body mass index (BMI), higher liver disease severity, and reduced handgrip strength (HGS) in unadjusted comparisons. Serum adiponectin was significantly higher in sarcopenic patients (9.3 ± 3.9 vs 5.8 ± 4.0 μg/mL; P < 0.001) and showed the best discrimination (AUROC = 0.76), outperforming follistatin (0.67), myostatin (0.63), low HGS (0.53), and low SMI by bioelectrical impedance analysis (0.62, all P < 0.05). A multivariable model incorporating adiponectin, BMI, and age further improved the diagnostic performance (AUROC = 0.87; P = 0.005) with good calibration (Hosmer-Lemeshow P = 0.31). CONCLUSIONS: Serum adiponectin is a promising noninvasive biomarker for sarcopenia in patients with compensated cirrhosis. A model integrating adiponectin, BMI, and age significantly enhances diagnostic accuracy and may serve as a practical screening tool for sarcopenia in this population.
Diagnostic Performance of Serum Adiponectin and a Biomarker-Based Model for Sarcopenia in Compensated Cirrhosis.
阅读:1
作者:Boonpiraks Kanachai, Thaweesukolrat Phatcharapong, Surinlert Piyaporn, Pranweerapaiboon Kanta, Siramolpiwat Sith
| 期刊: | Journal of Clinical and Experimental Hepatology | 影响因子: | 3.200 |
| 时间: | 2026 | 起止号: | 2026 May-Jun;16(3):103524 |
| doi: | 10.1016/j.jceh.2026.103524 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
